|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-3-23
|
|
pubmed:abstractText |
Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy. Several salvage therapies have been explored, but the optimal combination regimen has not been defined. We performed a case-matched study comparing patients with relapsed/refractory MM receiving thalidomide-dexamethasone alone or the combination thalidomide-dexamethasone-liposomal pegylated doxorubicin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0902-4441
|
|
pubmed:author |
pubmed-author:AvontoIlariaI,
pubmed-author:BoccadoroMarioM,
pubmed-author:BringhenSaraS,
pubmed-author:CorvattaLauraL,
pubmed-author:FalcoPatriziaP,
pubmed-author:LeoniPietroP,
pubmed-author:MarconiMonicaM,
pubmed-author:OffidaniMassimoM,
pubmed-author:PalumboAntonioA,
pubmed-author:PiersantelliMaria-NovellaMN,
pubmed-author:PolloniClaudiaC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
297-302
|
|
pubmed:meshHeading |
pubmed-meshheading:17286608-Aged,
pubmed-meshheading:17286608-Aged, 80 and over,
pubmed-meshheading:17286608-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17286608-Case-Control Studies,
pubmed-meshheading:17286608-Dexamethasone,
pubmed-meshheading:17286608-Disease Progression,
pubmed-meshheading:17286608-Disease-Free Survival,
pubmed-meshheading:17286608-Dose-Response Relationship, Drug,
pubmed-meshheading:17286608-Doxorubicin,
pubmed-meshheading:17286608-Female,
pubmed-meshheading:17286608-Follow-Up Studies,
pubmed-meshheading:17286608-Humans,
pubmed-meshheading:17286608-Liposomes,
pubmed-meshheading:17286608-Male,
pubmed-meshheading:17286608-Middle Aged,
pubmed-meshheading:17286608-Multiple Myeloma,
pubmed-meshheading:17286608-Polyethylene Glycols,
pubmed-meshheading:17286608-Recurrence,
pubmed-meshheading:17286608-Retrospective Studies,
pubmed-meshheading:17286608-Salvage Therapy,
pubmed-meshheading:17286608-Survival Rate,
pubmed-meshheading:17286608-Thalidomide,
pubmed-meshheading:17286608-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
|
|
pubmed:affiliation |
Clinica di Ematologia Polo Ospedaliero-Universitario, Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, Italy. m.offidani@ao-umbertoprimo.marche.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
